KCA
Search
- Page Path
- HOME > Search
Original Article
- Immunogenicity of Influenza Vaccine in Colorectal Cancer Patients
- Dong Ho Kim, Yun Yong Lee, Ui Sup Shin, Sun Mi Moon
- Cancer Res Treat. 2013;45(4):303-312. Published online December 31, 2013
- DOI: https://doi.org/10.4143/crt.2013.45.4.303
-
Abstract
PDF
PubReader
ePub - PURPOSE
Although influenza is regarded as a major cause of morbidity and mortality in immunocompromised patients, vaccine coverage remains poor. We evaluated the immunogenicity of influenza vaccines in colorectal cancer patients.
MATERIALS AND METHODS
In this study, 40 colorectal cancer patients who received an influenza vaccine at the Korea Cancer Center Hospital during the 2009-2010 and 2010-2011 influenza seasons were analyzed. The blood samples were collected at prevaccination and 30 days post vaccination, and antibody titers were measured using the hemagglutination-inhibition tests.
RESULTS
In the 2009-2011 season, the seroprotection rate for H1N1 (94.7%) was significantly higher than that for H3N2 (42.1%) and B (47.3%). The seroconversion rate was 52.6%, 26.3%, and 36.8% for H1N1, H3N2, and B, respectively. Fold increase of geometric mean titer (MFI) was 3.86, 1.49, and 3.33 for H1N1, H3N2, and B, respectively. In the 2010-2011 season, the seroprotection rate for H1N1 (57.1%) was significantly higher than that for H3N2 (52.4%) and B (38.1%). The seroconversion rate was 52.4%, 47.6% and 33.3% for H1N1, H3N2, and B, respectively. MFI was 12.29, 3.62 and 4.27 for H1N1, H3N2, and B, respectively.
CONCLUSION
Our study cohort showed an acceptable immune response to an influenza vaccine without significant adverse effects, supporting the recommendation for annual influenza vaccination in colorectal cancer patients. -
Citations
Citations to this article as recorded by
- Therapeutic vaccines for colorectal cancer: The progress and future prospect
Mina Shahnazari, Pouria Samadi, Mona Pourjafar, Akram Jalali
International Immunopharmacology.2020; 88: 106944. CrossRef - Vaccines for colorectal cancer: an update
Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
Journal of Cellular Biochemistry.2019; 120(6): 8815. CrossRef - Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season
Maria Ganczak, Paulina Dubiel, Marzena Drozd-Dąbrowska, Ewelina Hallmann-Szelińska, Karol Szymański, Lidia B. Brydak
International Journal of Environmental Research and Public Health.2019; 16(22): 4489. CrossRef - Immunogenicity of Influenza Vaccination in Patients With Cancer
Saiama N. Waqar, Leigh Boehmer, Daniel Morgensztern, Andrea Wang-Gillam, Steven Sorscher, Steven Lawrence, Feng Gao, Kalin Guebert, Kristina Williams, Ramaswamy Govindan
American Journal of Clinical Oncology.2018; 41(3): 248. CrossRef - Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy
Kei Nakashima, Masahiro Aoshima, Satoko Ohfuji, Kanzo Suzuki, Masahiro Katsurada, Naoko Katsurada, Masafumi Misawa, Yoshihito Otsuka, Kyoko Kondo, Yoshio Hirota
Human Vaccines & Immunotherapeutics.2017; 13(3): 543. CrossRef - Influenza vaccination in adult patients with solid tumours treated with chemotherapy
Albert Vollaard, Imke Schreuder, Lizzy Slok-Raijmakers, Wim Opstelten, Guus Rimmelzwaan, Hans Gelderblom
European Journal of Cancer.2017; 76: 134. CrossRef - Vaccination in Patients with Primary Immune Deficiency, Secondary Immune Deficiency and Autoimmunity with Immune Regulatory Abnormalities
Martha M Eibl, Hermann M Wolf
Immunotherapy.2015; 7(12): 1273. CrossRef
- Therapeutic vaccines for colorectal cancer: The progress and future prospect
- 44,737 View
- 59 Download
- 7 Crossref
First
Prev
